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ABSTRACT
Low response rates and concerns about safety have limited the implementation of treatment for chronic he-
patitis C (CHC) in patients with HIV infection. The efficacy and safety of pegylated interferon (peg-IFN) plus
ribavirin in HIV-infected patients with CHC were evaluated in a prospective, open-label, multicenter study.
Sixty patients with persistently high transaminases, positive HCV-RNA, CD4 count 300 cells/l, and HIV-
RNA 10,000 copies/ml were included. Patients were given peg-IFN 80–150 g/week plus ribavirin 800–1200
mg/day. Treatment was scheduled for 24 weeks for genotypes 2/3 and 48 weeks for genotypes 1/4. In an in-
tent-to-treat analysis, 16 (26.7%) patients achieved a sustained virological response (SVR). Twenty patients
(33.3%) discontinued treatment prematurely, but only in 10 (16.6%) was discontinuation due to adverse events.
Negative predictive values for SVR on the basis of HCV-RNA decline between baseline and week 4 were 100%
for 1- and 2-log10 fall, and positive predictive values were 40% and 58.3% for 1- and 2-log10 fall, respectively.
CD4 fell by a median of 216 cells during treatment, but no HIV-associated complications occurred. In con-
clusion, treatment with peg-IFN alfa-2b plus ribavirin is safe and clears RNA-HCV in about one-quarter of
HIV-infected patients with CHC. Efforts should be focused on optimizing management of side effects and
counseling to improve adherence and to keep patients on treatment. Assessment of HCV-RNA at week 4 may
help guide early therapeutic decision making.
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INTRODUCTION
AS A RESULT OF THE IMPROVED PROGNOSIS OF HIV DISEASEin the last decade, hepatitis C virus (HCV)-associated liver
disease has emerged as a leading cause of morbidity and mor-
tality in HIV/HCV coinfected patients.1–3 To avoid progression
to end-stages of liver disease, treatment with pegylated inter-
feron (peg-IFN) plus ribavirin is currently recommended for
chronic hepatitis C (CHC) in patients with preserved immune
status and a good control of HIV replication.4,5 However, low
virological response rates, the uncertainty surrounding long-
term efficacy, and concern regarding the safety of combined
therapy frequently dissuade clinicians from treating these pa-
tients.4 In addition to the well-recognized adverse events, the
increased risk of severe lactic acidosis, pancreatitis, and hepatic
decompensation in the course of treatment with concomitant
antiretroviral therapy is of special concern.6–8 The real extent
of this problem is unknown, but certain risk factors have been
identified, such as treatment with didanosine.8,9
In mid-2001, the encouraging results obtained in non-HIV
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patients10,11 prompted us to implement treatment of CHC in
HIV-coinfected patients with a combination of peg-INF and rib-
avirin in our hospital and associated centers. Since at that time
there was little experience with the combination in this popu-
lation, an open prospective study was started to evaluate its ef-
ficacy and safety. Here we report our experience of treatment
with peg-INF plus ribavirin for CHC in HIV-coinfected pa-
tients. We also evaluated the usefulness of RNA-HCV levels
at week 4 of treatment as a predictor of sustained virological
response (SVR) in a subset of patients.
MATERIALS AND METHODS
Study design
A prospective, open-label, multicenter study was conducted
in 10 hospitals in Spain, from November 2001 to October 2002.
The study was approved by the institutional review board at
each center and informed consent was obtained for each patient
recruited. All patients received the combination of pegylated
IFN-2b (Pegintron; Shering-Plough, Kenilworth, NJ) 80–150
g (less than 60 kg, 80 g; between 61 and 75 kg, 100 g; be-
tween 76 and 85 kg, 120 g, more than 85 kg, 150 g), once
a week subcutaneously, and ribavirin (Rebetol; Shering-Plough,
Kenilworth, NJ) 800–1200 mg (less than 65 kg, 800 mg/day;
between 66 and 85, 1000 mg/day, and more than 85 kg, 1200
mg/day) divided in two daily doses administered orally. Treat-
ment was scheduled for an initial period of 24 weeks for all pa-
tients. According to the guidelines established by the Advisory
Council for Treatment of Viral Hepatitis (Health Department
of the Government of Catalonia),12 treatment was discontinued
at week 24 in patients without virological response (see below)
and those with virological response harboring genotypes 2 and
3. In patients with genotypes 1 and 4 and virological response,
treatment was extended to 48 weeks.
End-points
The primary end-point of the study was the SVR, defined as
undetectable serum HCV-RNA 24 weeks after the end of treat-
ment. The secondary end-point was early virological response
(EVR), defined as a 1- or 2-log drop or undetectable HCV-RNA
at week 4 of treatment.
Patients
Adult patients between 18 and 60 years were eligible if they
had confirmed HIV infection, persistently elevated transami-
nase levels (on at least two occasions, 3 months apart), posi-
tive HCV antibodies, and detectable serum HCV RNA. Liver
biopsy was not mandatory. As for HIV infection, patients were
required to have 300 cells/l and HIV RNA levels below
10,000 copies/ml (b-DNA). Exclusion criteria included active
coinfection with hepatitis B virus, other liver diseases, decom-
pensated cirrhosis, concomitant treatment with zidovudine, ac-
tive drug abuse within the previous 12 months, alcohol intake,
history of severe psychiatric illness, seizures, autoimmune dis-
ease, previous therapy with interferon, white blood cell count
1500/mm3, platelet count 85,000/mm3, and hemoglobin
12 g/dl for women and 13 g/dl for men. Patients with serum
lactate more than four times above the upper limit, or twice the
normal limit if receiving concomitant treatment with didano-
sine, were also excluded.
Patients’ evaluation
Patients were evaluated as outpatients at weeks 2, 4, 12, and
every 3 months thereafter. Laboratory tests were performed in
each of the participating centers except for HCV RNA and
genotyping, which were centralized in the Microbiology De-
partment of the Hospital Universitari de Bellvitge. Serum HCV
was assessed by the qualitative test (detection limit 50 IU/ml;
Cobas Amplicor v2.0 kit, Roche Diagnostics Systems Inc.).
Serum HCV RNA quantitation was carried out with the Cobas
Amplicor HCV Monitor test v2.0 (Roche Molecular Systems,
Branchburg, NJ) with a detection limit of 600 IU/ml. HCV
genotyping was determined from the RNA extracted for quan-
titation using a test based on a restriction fragment length poly-
morphism (RFLP).13 Briefly, HCV RNA was amplified by a
nested RT-PCR on the 5 UTR region of the HCV genome to
obtain a 240-bp amplicon that was cleaved using three restric-
tion endonucleases (MvaI, Bsh1236I, and MboI). The fragment
pattern was analyzed by electrophoresis on agarose gels stained
with ethidium bromide.
Safety was assessed by recording clinical adverse events and
laboratory abnormalities. Severity of adverse events was graded
as mild, moderate, severe, or life-threatening. Adverse events
were evaluated for duration, relationship to the study medica-
tion, and action taken to relieve them. Stepwise reductions in
the peg-IFN and ribavirin, according to predefined thresholds,
were allowed for the management of adverse events. No growth
factors (such as erythropoietin or granulocyte colony-stimulat-
ing factor) were used to manage hematologic toxicity.
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FIG. 1. Study profile.
Statistical analysis
With our understanding of the combined therapy with peg-
IFN and ribavirin for CHC at the time of the study design, and
assuming a poorer response in the HIV-coinfected population,
we expected an SVR rate of 30%. It was estimated that a min-
imum of 56 patients (including 20% nonevaluable patients)
were needed to give results for the primary end-point (SVR)
within 15% of the confidence interval, with a confidence level
of 95% and a power of 80%. However, in case the drop-out
rate was higher than expected, recruitment of patients after
reaching the minimum sample size was allowed until the close
of the inclusion period. Efficacy and safety analyses were based
on the patients who received at least one dose of the study med-
ication. Response rates were determined on an intention-to-treat
basis. Patients lost to follow-up during the study period or with
missing HCV RNA determinations were treated as failures. Ad-
ditionally, an analysis based on the patients who completed the
scheduled treatment was also performed (on-treatment analy-
sis). The relation of baseline characteristics and SVR was as-
sessed by univariate and stepwise forward logistic-regression
analysis. Negative and positive predictive values (NPV and
PPV) were calculated by 2  2 tables. Statistical analyses were




Sixty-five patients were recruited, of whom 5 (7.7%) were
excluded (Fig. 1). The remaining 60 (92.3%) patients who took
at least one dose of medication were included in the analysis.
Most patients were men (80%), had acquired HIV infection by
an intravenous route (83.3%), and were receiving effective an-
tiretroviral therapy (90%). As for characteristics of HCV in-
fection, the only relevant finding was a lower HCV RNA in the
nine patients harboring genotype 4 (mean 5.23  0.81 log10,
median 5.4 log10) than in those with genotypes 1 and 3 (mean
6.24  0.46 log10, median 6.3; p  0.005). The main charac-
teristics of patients at baseline are summarized in Table 1.
Efficacy
Twenty patients (33.3%; 95% CI 21.4–45.3%) had unde-
tectable plasma HCV RNA at the end of treatment (EOT). At
6 months after stopping treatment, 16 patients (26.7%; 95% CI
15.5–37.9%) continued with undetectable HCV RNA levels and
were considered as having SVR. Virological response rates ac-
cording to genotype are shown in Table 2. Overall, out of 44
patients who failed to achieve SVR, 20 (45.5%) did not respond
at the end of treatment, 20 (45.5%) discontinued treatment pre-
maturely, and 4 (9.1%) initially responded but relapsed shortly
after stopping treatment. Premature treatment discontinuation
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TABLE 1. BASELINE CHARACTERISTICS OF THE 60 PATIENTS
Characteristics
Age, years mean (SD) 38.1 (5.3)
Sex, n (% male) 48 (80)
Weight, kg mean (SD) 71.7 (1.4)
Mode of infection, n (%)
Intravenous drug use 50 (83.3)
Sexual 8 (13.4)
Others 2 (3.4)
Estimated duration of HCV infection, n (%)
5–10 years 28 (46.7)
10 years 29 (48.3)
Unknown 3 (5)
ALT levels, IU/liter, mean (SD) 128.5 (66.2)
AST levels, IU/liter, mean (SD) 101.6 (69.9)
HCV RNA log10, IU/liter
Mean (SD) 6.06 (0.63)






CD4 cell count, cells/mm3, mean (SD) 645 (350.5)
HIV RNA log10, copies/ml, mean (SD) 2.17 (0.43)
Antiretroviral therapy, n (%)
2 NRTIs 	 1 NNRTI 36 (60)
2 NRTIs 	 1 IPa 10 (16.7)
3 NRTIs 6 (10)
Others 2 (3.4)
aOne patient received d4T, ddI, and a protease inhibitor.
TABLE 2. VIROLOGICAL RESPONSE AT THE END OF TREATMENT
AND FOLLOW-UP
On treatment Intent-to-treat
End of End of
treatment Sustained treatment Sustained
response response response response
Genotype n/N (%) n/N (%) n/N (%) n/N (%)
1 7/23 (30.4) 6/23 (26) 7/32 (21.8) 6/32 (18.7)
2 0/2 (—) 0/2 (—) 0/2 (—) 0/2 (—)
3 10/11 (90.9) 8/11 (72.7) 10/17 (58.8) 8/17 (45.1)
4 3/4 (75) 2/4 (50) 3/9 (33.3) 2/9 (22.2)
Overall 20/40 (50) 16/40 (40) 20/60 (33.3) 16/60 (26.7)
in 10 of 20 patients (50%) was at the patient’s request, or due
to losses to follow-up. Patients infected with genotype 3 and
with low plasma HCV RNA at baseline had a higher SVR rate.
Univariate and multivariate analyses of predictors of SVR are
shown in Table 3.
Predictive value of virological response at week 4
HCV-RNA level was assessed at week 4 in 48 patients.
Thirty-five (73%) and 25 (52%) patients had at least 1-log10
and 2-log10 reduction from baseline, respectively. There were
no significant differences between genotypes in the proportion
of patients who achieved 1 log10 reduction: 13 of 15 patients
(86.6%) with genotype 2/3 and 22 of 33 (66.7%) with geno-
type 1/4 had at least 1-log10 reduction from baseline (p  0.18).
But, there were differences when 2-log10 reduction was con-
sidered: 13 of 15 patients (87%) with genotypes 2/3 had at least
2-log10 reduction, as compared with 12 of 33 (36%) with geno-
types 1/4 (p  0.002). None of the 13 patients with less than 1
log10 HCV-RNA reduction and 14 of the 35 (40%) with at least
1-log10 reduction achieved SVR (p  0.01). When a cut-off of
a 2-log10 fall was considered, none of the 24 below this figure
achieved SVR, as compared to 14 of 24 (58.3%) above it (p 
0.001). NPVs were 100% (95% CI 72–100%) for 1 log10 re-
duction and 100% (95% CI 83–100% for 2 log10 reduction, and
PPVs were 40% (95% CI 24–57%) and 58% (95% CI 37–72%)
for 1 and 2 log10 reduction, respectively.
Safety
During treatment 57 patients (95%) presented adverse events,
which were serious (grade III/IV) in 10 (16.7%) (Table 4). Over-
all, dose reduction of medication due to adverse events was nec-
essary in 7 patients (11.7%), and permanent discontinuation of
one or two of the drugs in 10 (16.7%). Flu-like syndrome was
the most frequent adverse event observed (76.6% of cases), and
led to treatment discontinuation in two cases (3.2%). In addition
to these two cases, in four of five patients who asked to leave
the study, flu-like symptoms (though considered mild by the in-
vestigators) significantly contributed to their decision. As for
hematological alterations, only neutropenia reached grade III–IV
severity in three cases, and was responsible for treatment dis-
continuation in two. Six patients (10%) developed anemia dur-
ing treatment: none was severe and treatment discontinuation
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TABLE 3. PREDICTORS FACTORS OF SUSTAINED VIROLOGICAL RESPONSE (UNIVARIATE AND MULTIVARIATE ANALYSES)
Responders Crude RR Adjusted RR
Variable N N (%) (95% CI) p (95% CI) p
Age (years)
40 35 9 (25.7) 1
40 25 7 (28) 1.1 (0.4–3.6) 0.84
Sex
Female 12 1 (8.3) 1
Male 48 15 (31.3) 5.0 (0.6–42.3) 0.14
Weighta
70 27 7 (25.9) 1
70 30 9 (30) 1.2 (0.4–3.9) 0.73
HIV/HCV acquisition
Others 10 1 (10) 1
Intravenous drug use 50 15 (30) 3.9 (0.4–33) 0.22
AIDS
Yes 15 2 (13.3) 1
No 45 14 (31.1) 2.9 (0.6–14.8) 0.19
CD4 cell count (cells/mm3)b
500 36 9 (25) 1
500 23 7 (30.4) 1.3 (0.4–4.2) 0.65
Antiretroviral therapy
Yes 54 14 (25.9) 1
No 6 2 (33.39) 1.4 (0.2–8.7) 0.70
ALT (IU/ml) 60 16 (26.7) 1.0 (0.9–1.0) 0.26
Genotype 3
No 17 8 (47.1) 1 1
Yes 43 8 (18.6) 3.9 (1.1–13.2) 0.03 5.0 (1.3–19.9) 0.02
Plasma HCV RNA (UI/ml)
800,000 38 6 (15.8) 1 1
800,000 22 10 (45.5) 4.4 (1.3–14.9) 0.02 5.6 (1.5–21.2) 0.01
Treatment modification
(dose reduction)
No 53 14 (26.4) 1
Yes 7 2 (28.6) 1.1 (0.2–6.4) 0.90
aData available for 57 patients.
bData available for 59 patients.
was not necessary in any case. Hemoglobin levels decreased pro-
gressively from baseline to week 12: median 15.5 g/liter at base-
line, 13.3 g/liter at week 4, and 13.2 g/liter at week 12. No deaths,
lactic acidosis, pancreatitis, or new or unexpected adverse events
were seen. CD4 cell counts decreased by a median of 216 cells
from the baseline to the end of treatment (data assessed in 34 of
40 patients who completed treatment). No increases in HIV-
RNA were observed in any patient during treatment.
DISCUSSION
Our results show that the combination of peg-IFN alfa-2b
plus ribavirin clears HCV-RNA in about 25% of HIV-infected
patients with CHC. This response rate is lower than those re-
cently reported in coinfected subjects14,15 and in HCV single-
infected populations.10,11 The APRICOT study,14 a compara-
tive clinical trial of peg-IFN alfa-2a plus ribavirin with
combined standard therapy and peg-IFN alone in coinfected pa-
tients, reported an SVR rate of 40% in the peg-IFN alfa-2a plus
ribavirin arm. Similar results were found in another smaller
study comparing the combination of peg-IFN alfa-2b plus rib-
avirin with standard therapy.15 In contrast, data from the 
RIBAVIC study9 with peg-IFN alfa-2b plus ribavirin obtained
an SVR rate of 27%, a figure closer to ours and to those re-
ported previously in an open-label study.7 In addition to dif-
ferences in patients’ baseline characteristics, methodology,
therapeutic regimens, and study settings, premature discontin-
uation rates make a significant contribution to the huge dis-
crepancies in efficacy rates. Thirty-nine percent of patients
treated with peg-IFN and ribavirin discontinued treatment in
the RIBAVIC study, as compared to 25% in the APRICOT
study. In our series premature treatment discontinuation was
recorded in 33% of cases. Notably, half of the discontinuations
were at the patient’s request or due to losses to follow-up, a cir-
cumstance that probably reflects a lack of expertise on the part
of some treating teams in management and counseling aimed
at improving adherence and keeping patients on treatment.
As regards safety, the combination of peg-IFN alfa-2b plus
ribavirin was relatively well tolerated. However, psychiatric
disorders are of special concern, because of their potential
severity and the high rate of treatment discontinuation. No
deaths, life-threatening complications such as lactic acidosis
and pancreatitis,6–8,16 or new or unexpected adverse events were
seen. In addition, a high rate of liver decompensation in the
course of treatment was reported in coinfected patients with his-
tologically proven cirrhosis.8 Concomitant treatment with di-
danosine, increased bilirubin levels, decreased hemoglobin, 
increased alkaline phosphatase, or decreased platelets was iden-
tified as the major risk-associated factor.8 In our study, in which
no patients presented evidence of hepatic insufficiency before
initiation of treatment and only one received didanosine, none
of these major complications was seen.
As in previous reports, we found no opportunistic infections
during treatment, and the HIV viral load remained under con-
trol. However, given the high median CD4 cell count of the pa-
tients included, fewer than 10% fell below 200 cells despite a
pronounced decline during treatment. So HIV-associated com-
plications may appear if treatment is given to patients with
lower CD4 cell counts.
Two points of our study merit further comment: the duration
of treatment for genotypes 2 and 3 and the predictive value of
RNA-HCV at week 4 of treatment. A 24-week regimen for geno-
types 2 and 3 was adopted in the present study, following the
guidelines established by the local health authorities when the
study was designed. What our results indicate is that 24 weeks
of therapy is sufficient for some coinfected patients with geno-
type 2 or 3. However, as observational data17 show, relapses are
unexpectely high among patients treated for 24 weeks. So, un-
til prospective clinical trials are able to identify favorable re-
sponse factors that make it possible to shorten treatment for
genotypes 2 or 3, a 48-week therapy regimen should be offered
to all HIV-coinfected patients regardless of genotype.
As regards early virological response as a prognostic factor
of SVR, our data show that patients who did not have a sub-
stantial reduction of RNA-HCV by week 4 of treatment did not
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TABLE 4. ADVERSE EVENTS DURING TREATMENT
Cause of
Grade III or IV treatment
Adverse event N (%) events discontinuation
Flu-like symptoms 46 (76.6) 3 (5) 2 (3.3)
Weight loss 22 (36.6) —
Psychiatric disorders 20 (30) 3 (5) 4 (6.7)
Psychosis 4 1 3
Depression 8 1 1
Irritability/insomnia 9 — —
Hematological alterations 22 (36.6) 3 (5) 2 (3.3)
Anemia 6 —
Neutropenia 17 3 2
Thrombocytopenia 13 —
Respiratory symptoms 4 (6.6) 1 (1.6) 1 (1.7)
Dyspnea 4 1 1
Dermatological alterations 14 (23.3) — 1 (1.7)
Injection-site reaction 13
Generalized rash 1 1
achieve long-term response. Although the confidence interval
around this estimate is wide, these data strongly suggest that
assessment of HCV-RNA level at week 4 of treatment may ac-
curately identify patients with no chance of achieving SVR.
Since slow responses were reported in some patients, a 1-log
rather than 2-log reduction may be a more reliable cut-off to
identify patients with no chance of responding. These results
are in agreement with other recently published findings and
should be confirmed in larger controlled clinical trials.18 Mean-
while, treatment should be discontinued if a fall of at least 
2-log is not achieved by week 12.4
In summary, in our experience, the combination of peg-IFN
alfa-2b plus ribavirin clears HCV-RNA in about one-quarter of
HIV-infected patients with CHC. This low SVR was mainly re-
lated to a high drop-out rate; however, premature discontinua-
tion of treatment was due to serious adverse events in only 17%
of cases. Efforts should be focused on optimizing management
of side effects and counseling to improve adherence and keep
patients on treatment. Assessment of HCV-RNA level at week
4 of treatment may help guide early therapeutic decisions, and
merits further exploration in larger controlled clinical trials.
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